Company / Operating Cash Flow per Share
IOVANCE BIOTHERAPEUTICS, INC. Operating Cash Flow per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
-$0.99
FY2025
5-year range
-$1838.24 / -$0.99
FY2021-FY2025
Trend
+28.1%
vs FY2024
Sector context
#115 of 212
Health Care
What the data says
At $-0.99, IOVANCE BIOTHERAPEUTICS, INC.'s operating cash flow per share ranks #115 of 212 in the Health Care sector. Operating Cash Flow per Share has increased for 3 consecutive years, from $-1838.24 in FY2022 to $-0.99 in FY2025.
Based on SEC 10-K filings.
-0.99 in FY2025.
Improved from $-1.93 to $-0.99 over the past 2 years.
Health Care sector context is included.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#115 of 212 in Health CareTop 54% of 212This company -$0.99 Sector average $5.28
▼
-118.8% below sector average
Key checks
Key Insights
- IOVANCE BIOTHERAPEUTICS, INC.'s operating cash flow per share has grown for 3 consecutive years.
- In FY2025, operating cash flow per share increased 28.1% year-over-year.
- Ranks #115 out of 212 companies in the Health Care sector.
- Peak operating cash flow per share was recorded in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.05 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$0.99 | +28.1% |
| FY2024 | -$1.38 | +28.5% |
| FY2023 | -$1.93 | +99.9% |
| FY2022 | -$1838.24 | -23.7% |
| FY2021 | -$1485.87 | -0.2% |
| FY2020 | -$1483.24 | -16.1% |
| FY2019 | -$1277.90 | -92244.1% |
| FY2018 | -$1.38 | -9.4% |
| FY2017 | -$1.26 | -611.1% |
| FY2016 | -$0.18 | -63.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026